Comprehensive Stock Comparison
Compare BridgeBio Oncology Therapeutics Inc. (BBOT) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | REGN | Lower P/E (17.3x vs 21.8x) |
| Stability / Safety | BBOT | Beta 0.26 vs REGN's 0.58 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; BBOT pays no meaningful dividend |
| Momentum (1Y) | REGN | +12.4% vs BBOT's -9.2% |
| Efficiency (ROA) | REGN | 11.1% ROA vs BBOT's -23.7%, ROIC 12.4% vs -64.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer drugs targeting specific genetic mutations in tumors. It generates revenue primarily through research collaborations and licensing deals — with future income dependent on successful drug development and commercialization — though currently in pre-revenue stage as it advances its clinical pipeline. The company's competitive advantage lies in its specialized focus on difficult-to-target oncogenes like KRAS and PI3Kα, leveraging BridgeBio Pharma's broader platform for drug discovery and development.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
REGN and BBOT operate at a comparable scale, with $14.3B and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.3B |
| EBITDAEarnings before interest/tax | -$124M | $4.2B |
| Net IncomeAfter-tax profit | -$115M | $4.5B |
| Free Cash FlowCash after capex | -$96M | $3.2B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +25.7% |
| Net MarginNet income ÷ Revenue | — | +31.4% |
| FCF MarginFCF ÷ Revenue | — | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | -2.5% |
Valuation Metrics
At 18.8x trailing earnings, REGN trades at a 14% valuation discount to BBOT's 21.8x P/E.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $794M | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $793M | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | 21.80x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x |
| EV / EBITDAEnterprise value multiple | — | 21.64x |
| Price / SalesMarket cap ÷ Revenue | — | 7.50x |
| Price / BookPrice ÷ Book value/share | 0.88x | 2.72x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-26 for BBOT. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs BBOT's 4/9, reflecting strong financial health.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | +14.4% |
| ROA (TTM)Return on assets | -23.7% | +11.1% |
| ROICReturn on invested capital | -64.9% | +12.4% |
| ROCEReturn on capital employed | -83.3% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | -$2M | -$16.2B |
| Cash & Equiv.Liquid assets | $2M | $18.9B |
| Total DebtShort + long-term debt | $0 | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $9,843 for BBOT. Over the past 12 months, REGN leads with a +12.4% total return vs BBOT's -9.2%. The 3-year compound annual growth rate (CAGR) favors REGN at 1.1% vs BBOT's -0.5% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -18.4% | +0.8% |
| 1-Year ReturnPast 12 months | -9.2% | +12.4% |
| 3-Year ReturnCumulative with dividends | -1.6% | +3.4% |
| 5-Year ReturnCumulative with dividends | -1.6% | +69.8% |
| 10-Year ReturnCumulative with dividends | -1.6% | +104.7% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +1.1% |
Risk & Volatility
BBOT is the less volatile stock with a 0.26 beta — it tends to amplify market swings less than REGN's 0.58 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.2% from its 52-week high vs BBOT's 67.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.26x | 0.58x |
| 52-Week HighHighest price in past year | $14.87 | $821.11 |
| 52-Week LowLowest price in past year | $8.50 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +67.5% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 267K | 687K |
Analyst Outlook
Wall Street rates BBOT as "Buy" and REGN as "Buy". Consensus price targets imply 132.6% upside for BBOT (target: $23) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | BBOTBridgeBio Oncolog… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $23.33 | $857.17 |
| # AnalystsCovering analysts | 2 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 24 | Feb 26 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 118.06 | +18.1% |
| Regeneron Pharmaceu… (REGN) | 100 | 76.82 | -23.2% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs BridgeBio Oncology … (BBOT)'s -2%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | $0.00 | $0.00 | — |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | -0 | 0.46 | +22004.8% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 5Free Cash Flow — 5 Years
BridgeBio Oncology Therapeutics Inc. generated $-1M FCF in 2024. Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
BBOT vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BBOT or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BBOT or REGN?
On trailing P/E, Regeneron Pharmaceuticals, Inc. (REGN) is the cheapest at 18.8x versus BridgeBio Oncology Therapeutics Inc. at 21.8x.
03Which is the better long-term investment — BBOT or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -1.6% for BridgeBio Oncology Therapeutics Inc. (BBOT). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus BBOT's -1.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BBOT or REGN?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc. (BBOT) is the lower-risk stock at 0.26β versus Regeneron Pharmaceuticals, Inc.'s 0.58β — meaning REGN is approximately 125% more volatile than BBOT relative to the S&P 500.
05Which has better profit margins — BBOT or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 0.0% for BridgeBio Oncology Therapeutics Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 0.0% for BBOT. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BBOT or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for BBOT: 132.6% to $23.33.
07Which pays a better dividend — BBOT or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. BBOT does not pay a meaningful dividend and should not be held primarily for income.
08Is BBOT or REGN better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc. (BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.26)). Both have compounded well over 10 years (BBOT: -1.6%, REGN: +104.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BBOT and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.